Institution scientifique

Oryzon Genomics (Spain)

Cornellà de Llobregat · ES · company

264Publications signalées

19112Citations signalées

12Thèmes principaux

Principaux domaines

HER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesEpigenetics and DNA MethylationHistone Deacetylase Inhibitors ResearchAcute Myeloid Leukemia ResearchCancer Treatment and PharmacologyCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsRetinal Development and DisordersMonoclonal and Polyclonal Antibodies ResearchImmunotherapy and Immune Responses

Évolution annuelle

2004 1

2005 3

2006 2

2007 2

2008 2

2009 6

2010 1

2011 2

2012 2

2013 5

2014 2

2015 6

2016 6

2017 4

2018 5

2019 20

2020 17

2021 10

2022 31

2023 37

2024 36

2025 40

2026 20

Publications récentes

2026 articleOpenAlex

Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer

Paolo Tarantino, Tianyu Li, Laia Paré Brunet, Esther Sanfeliu et autres

0 citationsEuropean Journal of Cancer

2026 articleOpenAlex

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR

Nadine Tung, Fengmin Zhao, Angela DeMichele, Olga Martínez‐Sáez et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 preprintOpenAlex

Immune organization defines adaptive immune competence and clinical outcome in breast cancer

Esther Sanfeliu, Elia Seguí, Anabel Martínez-Romero, Víctor Albarrán et autres

0 citationsmedRxiv

2026 articleOpenAlex

L26/O-334 A reference-free, 3D genome-based method and clinical application for haplotype phasing and carrier status determination of structural rearrangements in preimplantation genetic testing

S. Lu, Y. Wang, Y. Xia, Y. Chen et autres

0 citationsHuman Reproduction

2026 articleOpenAlex

L26/P-657 High-precision reconstruction of structural variations via one-step integrated analysis based on 3D genome

X. Bao, W. Niu, Y. Wang, H. Shi et autres

0 citationsHuman Reproduction

Accès ouvert 2026 articleOpenAlex

60P Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) with HER2DX in early-stage HER2-positive breast cancer: A prospective decision-impact subcohort analysis

O. Martinez Saez, M. Tapia, M. Marin, E. Hernández-Illán et autres

0 citationsESMO Open

Accès ouvert 2026 articleOpenAlex

54P Real-world pCR outcomes and predictive performance of the HER2DX pCR likelihood score in early-stage HER2-positive breast cancer: A multicenter prospective subanalysis

O. Martinez Saez, M. Tapia, M. Marin, E. Sanfeliu Torres et autres

0 citationsESMO Open

Accès ouvert 2026 articleOpenAlex

Quantitative HER2 tissue and plasma profiling predicts the activity of trastuzumab deruxtecan for breast cancer

Paolo Tarantino, Se-Eun Kim, Melissa E. Hughes, Ross J. Kusmick et autres

2 citationsnpj Precision Oncology

2026 conference-abstractOpenAlex

Abstract PS4-01-07: Prospective Validation of HER2DX in Early HER2+ Breast Cancer: Operational Feasibility of Centralized Genomic Screening in the DEFINITIVE Trial. Real-Time Insights from the First 80 Screened Patients

M. Gonzalez Rodriguez, K. Amilliano, S. Pernas, Pilar Menchón Sánchez et autres

0 citationsClinical Cancer Research

2026 conference-abstractOpenAlex

Abstract PS5-01-23: Validation of the HER2DX Genomic Test in First-Line Advanced HER2-Positive Breast Cancer: Identifying Long-Term Responders to THP

Marcin Kubeczko, Sandra Cobo, Rodrigo Sánchez-Bayona, Bartłomiej Pyciński et autres

0 citationsClinical Cancer Research

2026 conference-abstractOpenAlex

Abstract PS3-10-24: Biologic and Pathologic Correlations of the HER2DX Genomic Test in HER2+ Disease

E. Sanfeliu, Anabel Martínez-Romero, M. Marín-Aguilera, Sandra Cobo et autres

0 citationsClinical Cancer Research

2026 conference-abstractOpenAlex

Abstract PS5-01-08: Development of the HER2DX Predictor of Brain Metastasis in Advanced HER2-Positive Breast Cancer Treated with First-Line THP

Rodrigo Sánchez-Bayona, Sandra Cobo, Marcin Kubeczko, Jesús Soberino et autres

0 citationsClinical Cancer Research

Site officiel Identifiant ROR

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.